Travere Therapeutics (NASDAQ:TVTX) Releases Quarterly Earnings Results, Beats Expectations By $0.42 EPS

Travere Therapeutics (NASDAQ:TVTX) announced its earnings results on Thursday. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.42, FiscalAI reports. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The firm had revenue of $129.69 million for the quarter, compared to analyst estimates of $147.68 million. During the same quarter in the previous year, the firm posted ($0.47) EPS. The company’s revenue for the quarter was up 73.4% compared to the same quarter last year.

Here are the key takeaways from Travere Therapeutics’ conference call:

• Record commercial momentum for FILSPARI with 908 new patient starts in Q4 and ~$322M in full‑year 2025 net product sales (144% YoY), driven by physician adoption, REMS simplification, and KDIGO guidance.
• The sNDA for FSGS received a major amendment and additional FDA information requests, moving the PDUFA target action date to April 13, 2026, though management says it remains confident in FILSPARI’s clinical profile.
• Development progress on pegtibatinase — manufacturing optimizations complete and site activation for the pivotal phase 3 HARMONY study has resumed, with dosing of new patients expected to restart soon for this potential disease‑modifying HCU therapy.
• Financially strong quarter — Q4 non‑GAAP net income of $33.3M, year‑end cash and marketable securities of ~$322.8M, no near‑term need for additional capital, and guidance for moderate opex growth to support trials and a potential FSGS launch.

Travere Therapeutics Stock Up 5.1%

Shares of TVTX traded up $1.43 on Thursday, hitting $29.30. 2,596,730 shares of the stock traded hands, compared to its average volume of 2,497,540. Travere Therapeutics has a one year low of $12.91 and a one year high of $42.13. The company has a market capitalization of $2.62 billion, a PE ratio of -27.64, a P/E/G ratio of 0.79 and a beta of 0.83. The business has a 50 day simple moving average of $32.88 and a 200 day simple moving average of $28.74. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75.

Insider Buying and Selling at Travere Therapeutics

In other news, CFO Christopher R. Cline sold 1,745 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $32.19, for a total value of $56,171.55. Following the completion of the sale, the chief financial officer directly owned 111,226 shares in the company, valued at $3,580,364.94. The trade was a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jula Inrig sold 1,779 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $32.21, for a total transaction of $57,301.59. Following the completion of the sale, the insider directly owned 105,706 shares of the company’s stock, valued at approximately $3,404,790.26. This trade represents a 1.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 331,925 shares of company stock worth $11,318,755. Insiders own 4.19% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC increased its position in Travere Therapeutics by 69.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock worth $45,000 after buying an additional 487 shares in the last quarter. State of Wyoming bought a new position in shares of Travere Therapeutics during the 4th quarter valued at approximately $37,000. Captrust Financial Advisors increased its holdings in Travere Therapeutics by 9.3% in the 4th quarter. Captrust Financial Advisors now owns 20,703 shares of the company’s stock worth $791,000 after acquiring an additional 1,767 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Travere Therapeutics during the 2nd quarter worth approximately $33,000. Finally, Swiss National Bank raised its stake in Travere Therapeutics by 1.6% during the 3rd quarter. Swiss National Bank now owns 163,600 shares of the company’s stock worth $3,910,000 after acquiring an additional 2,500 shares during the period.

Analyst Ratings Changes

Several analysts have weighed in on the company. Zacks Research cut Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Wall Street Zen upgraded Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Piper Sandler boosted their target price on shares of Travere Therapeutics from $35.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $47.00 target price on shares of Travere Therapeutics in a research report on Friday, November 28th. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.62.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.